Asia-Pacific gets new weapon in fight against drug-resistant TB
A faster and vastly more effective treatment for drug-resistant tuberculosis is being rolled out in the Asia-Pacific region, raising hopes of a "new era" in tackling one of the world's deadliest infectious diseases.
PeerLINC Knowledge Hub Launched in Manila
The newly inaugurated PeerLINC Knowledge Hub in Manila is poised to harness local expertise and experience to catalyze the adoption of advanced and more efficacious cures for tuberculosis (TB) on a global scale.
Good News for Drug-Resistant TB Patients
March 25, 2024, was the launching of the PeerLinc Knowledge Hub, (Peer-to-peer Learning for Innovative Cures for TB), a project of the TB Alliance which has identified the Tropical Disease Foundation (TDF) to host the project in the Philippines.
New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World
TB Alliance’s new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding from the Australian Government through the Partnerships for a Healthy Region initiative.
Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB
The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million grant to support work with TB Alliance through its Product Development and Access Partnerships program.
USAID Secures $18 Million in New Funding to Accelerate Efforts to End Tuberculosis
A survey of national tuberculosis (TB) program staff members projects consistent global growth in the use of shorter, all-oral drug regimens for drug-resistant TB (DR-TB), but national efforts to ensure the new treatments are accessible to eligible patients are needed, researchers reported late last week in PLOS One.
Experts project growth in uptake of shorter, all-oral regimens for resistant TB
A survey of national tuberculosis (TB) program staff members projects consistent global growth in the use of shorter, all-oral drug regimens for drug-resistant TB (DR-TB), but national efforts to ensure the new treatments are accessible to eligible patients are needed, researchers reported late last week in PLOS One.
High Cure Rate with Drug-Resistant TB Regimen: Results of Operational Research in Central and Southeast Asia
Interim operational research results from five Central and Southeast Asian countries show that the new, shorter drug-resistant tuberculosis (TB) treatment – BPaL (comprised of bedaquiline, pretomanid, and linezolid) – had a 94.5% cure rate in countries with a high burden of drug-resistant TB (DR-TB).
‘My world looks like a TV with no signal after infection stole my sight’
A ‘dream come true’ drug is on the brink of a national rollout in the Philippines, and could transform life for thousands with resistant TB
Kyrgyzstan, Ukraine, and Uzbekistan Update National Guidelines for Drug-Resistant TB Treatment to Advance National Rollout of Three-Drug, Six-Month Regimen
— Kyrgyzstan, Ukraine, and Uzbekistan — participants in the LIFT-TB project — have updated their National Tuberculosis (TB) Clinical Guidelines to endorse the all-oral, six-month BPaL/M (bedaquiline + pretomanid + linezolid ± Moxifloxacin) regimen(s) as the national standard for treating most patients with drug-resistant tuberculosis (DR-TB).
The Lancet Profiles Successful tuberculosis treatment in Ukraine
While the new BPaL regimen is showing high effectiveness in the treatment of tuberculosis in Ukraine, the war threatens to hamper the success in the long term
Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment
Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34%.